These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36734462)

  • 1. Effects of somatostatin receptor type 2 antagonism during insulin-induced hypoglycaemia in male rats with prediabetes.
    Hoffman EG; D'Souza NC; Aiken J; Atherley S; Liggins R; Riddell MC
    Diabetes Obes Metab; 2023 Jun; 25(6):1547-1556. PubMed ID: 36734462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptor type 2 antagonism improves glucagon and corticosterone counterregulatory responses to hypoglycemia in streptozotocin-induced diabetic rats.
    Yue JT; Burdett E; Coy DH; Giacca A; Efendic S; Vranic M
    Diabetes; 2012 Jan; 61(1):197-207. PubMed ID: 22106159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin Receptor Antagonism Reverses Glucagon Counterregulatory Failure in Recurrently Hypoglycemic Male Rats.
    Hoffman EG; Jahangiriesmaili M; Mandel ER; Greenberg C; Aiken J; D'Souza NC; Pasieka A; Teich T; Chan O; Liggins R; Riddell MC
    Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34477204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor type 2 antagonism improves glucagon counterregulation in biobreeding diabetic rats.
    Karimian N; Qin T; Liang T; Osundiji M; Huang Y; Teich T; Riddell MC; Cattral MS; Coy DH; Vranic M; Gaisano HY
    Diabetes; 2013 Aug; 62(8):2968-77. PubMed ID: 23630299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZT-01: A novel somatostatin receptor 2 antagonist for restoring the glucagon response to hypoglycaemia in type 1 diabetes.
    Farhat R; Aiken J; D'Souza NC; Appadurai D; Hull G; Simonson E; Liggins RT; Riddell MC; Chan O
    Diabetes Obes Metab; 2022 May; 24(5):908-917. PubMed ID: 35060297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon responses to exercise-induced hypoglycaemia are improved by somatostatin receptor type 2 antagonism in a rat model of diabetes.
    Leclair E; Liggins RT; Peckett AJ; Teich T; Coy DH; Vranic M; Riddell MC
    Diabetologia; 2016 Aug; 59(8):1724-31. PubMed ID: 27075449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    Diabetes Obes Metab; 2014 Sep; 16(9):812-8. PubMed ID: 24612221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of hypoglycemia via somatostatin receptor type 2 antagonism in recurrently hypoglycemic diabetic rats.
    Yue JT; Riddell MC; Burdett E; Coy DH; Efendic S; Vranic M
    Diabetes; 2013 Jul; 62(7):2215-22. PubMed ID: 23434929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
    Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
    Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).
    Rodbard HW; Tripathy D; Vidrio Velázquez M; Demissie M; Tamer SC; Piletič M
    Diabetes Obes Metab; 2017 Oct; 19(10):1389-1396. PubMed ID: 28345792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
    Krentz AJ; Morrow L; Petersson M; Norjavaara E; Hompesch M
    Diabetes Obes Metab; 2014 Nov; 16(11):1096-101. PubMed ID: 24909093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptomatic and counterregulatory hormonal responses to acute hypoglycaemia induced by insulin aspart and soluble human insulin in Type 1 diabetes.
    Frier BM; Ewing FM; Lindholm A; Hylleberg B; Kanc K
    Diabetes Metab Res Rev; 2000; 16(4):262-8. PubMed ID: 10934454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon response to hypoglycemia is improved by insulin-independent restoration of normoglycemia in diabetic rats.
    Shi ZQ; Rastogi KS; Lekas M; Efendic S; Drucker DJ; Vranic M
    Endocrinology; 1996 Aug; 137(8):3193-9. PubMed ID: 8754739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can somatostatin antagonism prevent hypoglycaemia during exercise in type 1 diabetes?
    Taleb N; Rabasa-Lhoret R
    Diabetologia; 2016 Aug; 59(8):1632-5. PubMed ID: 27153841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of activated glucose counterregulation on insulin requirements in insulin-dependent diabetes mellitus.
    Bolli GB; Perriello G
    Horm Metab Res Suppl; 1990; 24():87-96. PubMed ID: 2272633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.
    Farngren J; Persson M; Ahrén B
    Diabetes Care; 2016 Feb; 39(2):242-9. PubMed ID: 26537183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial.
    Korsatko S; Jensen L; Brunner M; Sach-Friedl S; Tarp MD; Holst AG; Heller SR; Pieber TR
    Diabetes Obes Metab; 2018 Nov; 20(11):2565-2573. PubMed ID: 29893488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous GLP-1 levels play an important role in determining the efficacy of DPP-IV Inhibitors in both prediabetes and type 2 diabetes.
    Chong SC; Sukor N; Robert SA; Ng KF; Kamaruddin NA
    Front Endocrinol (Lausanne); 2022; 13():1012412. PubMed ID: 36267570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal glucagon as a viable alternative for treating insulin-induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: A phase 3 randomized crossover study.
    Matsuhisa M; Takita Y; Nasu R; Nagai Y; Ohwaki K; Nagashima H
    Diabetes Obes Metab; 2020 Jul; 22(7):1167-1175. PubMed ID: 32115879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.